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Purpose: We report a case of infectious endophthalmitis that developed after the third 
intravitreal injection of bevacizumab. The endophthalmitis was caused by Staphylococcus 
epidermidis.
Methods: Observational case series.
Results: This was a case of a 77-year-old man who had received three intravitreal injections of 
bevacizumab and developed infectious endophthalmitis. Polymerase chain reaction of an aque-
ous humor sample showed that the endophthalmitis was caused by S. epidermidis. The patient 
received intravitreal ceftazidime and vancomycin, and subconjunctival injection of vancomy-
cin. After the intravitreal injections he was treated with topical levofloxacin and cefmenoxime 
hydrochloride, and intravenous cefpirome. Subsequently, the ocular inflammation gradually 
decreased and his visual acuity remained at 30/200.
Conclusions: Our findings indicate that endophthalmitis can develop after intravitreal 
bevacizumab injections. Polymerase chain reaction is useful for differentiation from sterile 
endophthalmitis.
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Introduction
Intravitreal bevacizumab is now widely used to treat macular edema secondary to dif-
ferent pathological conditions including diabetic retinopathy, venous occlusive disease, 
and uveitis. However, infectious endophthalmitis can occur following any ocular sur-
gical procedure including intravitreal injection.1 Noninfectious endophthalmitis after 
intravitreal injection sometimes shows similar symptoms such as sudden decreased 
vision. Therefore, it is important to make a prompt differentiation between infectious 
and noninfectious endophthalmitis.
We report a case of endophthalmitis that developed after the third intravitreal injec-
tion of bevacizumab. The endophthalmitis was caused by Staphylococcus epidermidis, 
which was identified by using polymerase chain reaction (PCR).
Case report
A 77-year-old man had undergone uncomplicated phacoemulsification with implanta-
tion of a posterior chamber intraocular lens (IOL) in both eyes followed by Nd:YAG 
laser posterior capsulotomy in his right eye. He was referred to the Gifu University 
Graduate School of Medicine on May 24, 2007 with a complaint of blurred vision in 
his right eye. He had suffered from systemic hypertension and diabetes mellitus. Our Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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initial examination showed that his best-corrected visual 
acuity was 20/100 OD and 20/32 OS. Fundus examination 
revealed the scars of panretinal photocoagulation (PRP), 
and residual macular edema secondary to a central retinal 
vein occlusion in his right eye. He received two intravitreal 
injections of bevacizumab on May 31, 2007 and December 
11, 2007, and underwent pars plana vitrectomy on March 
5, 2008. Although his best-corrected visual acuity was 
restored to 20/40 in the right eye, ophthalmoscopy and by 
optical coherence tomography showed that the macular 
edema had recurred two months after the vitreous surgery. 
The patient did agree to a third intravitreal bevacizumab 
injection, which was given on October 14, 2008. Two days 
later the patient returned to our hospital complaining of 
decreased vision in his right eye. Examination showed 
that his best-corrected visual acuity was 20/200 in the 
right eye with mild ciliary injection and moderate non-
granulomatous inflammation of the anterior chamber. Slit-
lamp examination also showed hypopyon and mutton-fat 
keratic precipitates (KP). The fundus of the right eye was 
not visible because of corneal folds and a moderate anterior 
chamber inflammation.
He was immediately admitted into our hospital and 
received intravitreal ceftazidime and vancomycin, and 
subconjunctival vancomycin. He was started on topical 
levofloxacin and cefmenoxime hydrochloride, and intrave-
nous cefpirome (CPR). The ocular inflammation gradually 
decreased, but the intravenous antibiotic was continued for 
two additional weeks and then replaced by oral therapy. At 
three months, his best-corrected visual acuity remained at 
30/200. Although cultures and broad-range PCR failed to 
detect any bacterial pathogens, the DNA of S. epidermidis 
was detected in the aqueous humor sample by PCR using each 
specific primer against S. aureus and S. epidermidis.
Discussion
The development of infectious endophthalmitis after an 
intravitreal bevacizumab injection has been reported. Fin-
tak and colleagues describe three cases of endophthalmitis 
following an intravitreal injection of bevacizumab, and the 
incidence was calculated to be 0.02%.2 Two of their cases 
were caused by S. viridans and one by S. epidermidis.2 The 
incidence of endophthalmitis following intravitreal bevaci-
zumab injection in large case series was reported to be 0.019 
and 0.099%.3–5 Wickremasinghe et al reported the develop-
ment of acute intraocular inflammation in 19 of 1278 (0.1%) 
cases who had had an intravitreal bevacizumab injection.6 
Five of the cases were severe, and cultures of the vitreous 
aspirate detected Propionbacterium acnes in two cases, 
coagulase-negative staphylococcus species in one case, and 
no microbial growth in two cases. Sterile endophthalmitis 
after repeated intravitreal injections of bevacizumab injec-
tion has also been reported.7 In our department, a total of 
413 intravitreal injections of bevacizumab were undertaken 
between March 2007 and November 2009. Of those, only 
this case developed bacterial endophthalmitis following 
bevacizumab intravitreal injections. No eyes had acute 
intraocular inflammation in our series. The incidence of 
endophthalmitis following intravitreal bevacizumab injec-
tion in our case series was 0.24%, which was slightly higher 
than other reports. In our case that developed endophthal-
mitis, the prompt identification of S. epidermidis in the 
aqueous humor aspirate by PCR could lead to appropriate 
management.
The risk of infectious endophthalmitis is always a 
concern when an intraocular procedure is performed. An 
improvement of the sterilizing procedures should help mini-
mize the adverse event. This includes both pre-, intra-, and 
postoperative procedures.8 In this instance, we supposed an 
inadequate sterilization as the possible source of infectious 
endophthalmitis. Thereafter special care is taken with the 
additional administration of topical antibiotics three days 
before the operation, the complete covering of eyelashes 
with a sterile drape, and the use of 5% povidone iodine for 
a few minutes before surgery. Our case demonstrates that 
endophthalmitis can develop after intravitreal injection of 
bevacizumab, and PCR is useful for differentiation from 
sterile endophthalmitis.
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